Dimetindene

Dimetindene
Clinical data
Trade names	Fenistil
AHFS/Drugs.com	International Drug Names
Routes of; administration	Oral, topical
ATC code	D04AA13 (WHO) R06AB03 (WHO);
Legal status
Legal status	AU: S4 (Prescription only); UK: General sales list (GSL, OTC);
Identifiers
	IUPAC name N,N-Dimethyl-2-[3-(1-pyridin-2-ylethyl)-1H-inden-2-yl]ethan-1-amine;
CAS Number	5636-83-9 3614-69-5;
PubChem CID	21855;
DrugBank	DB08801 ;
ChemSpider	20541 ;
UNII	661FH77Z3P;
KEGG	D07853 ;
ChEMBL	ChEMBL22108 ;
CompTox Dashboard (EPA)	DTXSID9022942 ;
ECHA InfoCard	100.024.622
Chemical and physical data
Formula	C20H24N2
Molar mass	292.426 g·mol−1
3D model (JSmol)	Interactive image;
Chirality	Racemic mixture
	SMILES n1ccccc1C(C=3c2ccccc2CC=3CCN(C)C)C;
	InChI InChI=1S/C20H24N2/c1-15(19-10-6-7-12-21-19)20-17(11-13-22(2)3)14-16-8-4-5-9-18(16)20/h4-10,12,15H,11,13-14H2,1-3H3 ; Key:MVMQESMQSYOVGV-UHFFFAOYSA-N ;
	(verify)

Dimetindene, also sold under the brand name Fenistil, is an antihistamine/anticholinergic. It is a first generation^[1] selective H1 antagonist.^[2] Dimetindene is an atypical first generation H1 antagonist as it only minimally^[3] passes across the blood–brain barrier.

Dimetindene is also an M2 receptor antagonist.^[4]

It was patented in 1958 and came into medical use in 1960.^[5]

^ Fromer LM, Ortiz GR, Dowdee AM (September 2008). "Assessment of Patient Attitudes About Mometasone Furoate Nasal Spray: The Ease-of-Use Patient Survey". The World Allergy Organization Journal. 1 (9): 156–159. doi:10.1186/1939-4551-1-9-145. PMC 3651039. PMID 23282579.
^ "Dimetindene". Drugs.com.
^ Noguchi S, Inukai T, Kuno T, Tanaka C (June 1992). "The suppression of olfactory bulbectomy-induced muricide by antidepressants and antihistamines via histamine H1 receptor blocking". Physiology & Behavior. 51 (6): 1123–1127. doi:10.1016/0031-9384(92)90297-f. PMID 1353628. S2CID 29562845.
^ Matsumoto Y, Miyazato M, Furuta A, Torimoto K, Hirao Y, Chancellor MB, Yoshimura N (April 2010). "Differential roles of M2 and M3 muscarinic receptor subtypes in modulation of bladder afferent activity in rats". Urology. 75 (4): 862–867. doi:10.1016/j.urology.2009.12.013. PMC 2871158. PMID 20156651.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 547. ISBN 9783527607495.